Clinical Cancer Research Meeting Calendar Metabolism
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gumireddy, K.
Right arrow Articles by Reddy, C. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gumireddy, K.
Right arrow Articles by Reddy, C. D.
Clinical Cancer Research Vol. 9, 4052-4059, September 15, 2003
© 2003 American Association for Cancer Research

Experimental Therapeutics, Preclinical Pharmacology

All-trans-Retinoic Acid-induced Apoptosis in Human Medulloblastoma

Activation of Caspase-3/Poly(ADP-ribose) Polymerase 1 Pathway1

Kiranmai Gumireddy, Leslie N. Sutton, Peter C. Phillips and C. Damodar Reddy2

Fels Institute for Cancer Research and Molecular Biology, Temple University School of Medicine, Philadelphia, Pennsylvania 19140 [K. G.], and Division of Neuro-Oncology, The Children’s Hospital of Philadelphia [P. C. P., C. D. R.] and Department of Neurosurgery, University of Pennsylvania [L. N. S., C. D. R.], Philadelphia, Pennsylvania 19104

ABSTRACT

Current treatments for childhood brain tumor medulloblastoma (MB), radiation and chemotherapy, lead to undesirable side effects. Identification of antitumor agents that reduce the toxicity will thus have significant therapeutic value. In this study, we investigated all-trans-retinoic acid (ATRA) as an antitumor agent. Although high concentrations (1–10 µM) of retinoic acid derivatives are generally needed for significant antitumor effects in many cancer cells, we observed that pharmacologically relevant concentrations of ATRA were effective in inducing cell death in human MB cells. Using 10-fold lower concentrations (100–500 nM), we found that ATRA inhibits MB (DAOY, D283, D425, and D458) cell proliferation as determined by cell viability [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] and bromodeoxyuridine incorporation assays. Furthermore, 100 nM ATRA was potent in inhibiting the anchorage-independent growth of the sensitive cell lines (D283, D425, and D458) in soft agar assays. We also demonstrate that the ATRA-induced decrease in cell viability was due to increased cell death by apoptosis, which was accompanied by a 20-fold induction of caspase-3 activity in the most sensitive cell line, D458. By contrast, induction of caspase-3 was only 2-fold in the relatively insensitive DAOY cells. Furthermore, ATRA-induced cell death in D283, D425, and D458 cells was accompanied by activation of caspase-3, a key executioner of apoptosis. We also demonstrate that activated caspase-3 resulted in cleavage of 116-kDa poly(ADP-ribose) polymerase 1 to its signature fragments (85 and 29 kDa). Pretreatment with a specific caspase-3 inhibitor, DEVD-CHO, significantly reduced ATRA-induced apoptotic cell death. Thus, we demonstrate for the first time that low concentrations of ATRA inhibit MB cell proliferation and induce apoptotic cell death in part by activating caspase-3/poly(ADP-ribose) polymerase 1 effector pathway, and we show that retinoic acids and novel retinoids are potential antitumor agents in MB therapy.

Introduction

MBs3 are the most common malignant brain tumors of childhood with neuronal and glial differentiation that account for more than 20% of pediatric brain tumors. Despite multimodal treatment that includes surgery, radiation, and chemotherapy, tumor recurrence is frequent, and the majority of these patients eventually die from progressive tumor. Adverse neurocognitive effects are common in the long-term survivors (1) . Therefore, identification of antitumor agents with minimal toxicities is beneficial for the long-tem survivors. Aberrations in normal differentiation and apoptosis of primitive neuroectodermal cells are implicated in the pathogenesis of neuroblastomas and MBs (2, 3, 4) . Apoptotic cell death is often observed in primary MB tissue. However, the factors that initiate apoptosis and the regulatory pathways, which represent prime targets for therapeutic intervention, are poorly understood (2) . RA derivatives (retinoids) exert antitumor effects by inhibiting cell proliferation and inducing differentiation, cell growth arrest, and apoptosis. The effect of retinoids in neuroblastoma is well documented, and many cell lines are used as model systems to study neuronal differentiation and apoptosis (4 , 5) . In contrast, the role of retinoids and their receptors in MBs is poorly understood. The overall aim of our studies is to investigate the therapeutic potential of retinoids and to understand the mechanisms of their action in MB.

Retinoids represent a major class of chemopreventive agents, which exert strong antitumor activity by suppressing in vivo tumor growth (6, 7, 8) . The biological effects of retinoids in target cells are mediated by binding to RARs (RAR-{alpha}, -ß, and -{gamma}) and RXRs (RXR-{alpha}, -ß, and -{gamma}). Both ATRA and 9-cis-RA activate RARs, whereas 9-cis-RA activates RXRs. Both classes of these receptors are sequence-specific, ligand-activated transcription factors (9) . The presence of multiple isoforms of RXR and RAR provides potential for complex modulation of signaling by retinoids (10) . The spatiotemporal developmental expression pattern and tissue distribution of retinoid receptors suggest that various isoforms of the receptors might play different roles in mediating retinoid signaling (11) . RAR-{alpha} is expressed ubiquitously in adult tissues, RAR-{gamma} is expressed in skin, and RAR-ß is expressed in epithelial cells. Altered retinoid receptor expression has been linked to tumor development (6 , 7 , 12) . RAR-{alpha} has been shown to be critical in acute promyelocytic leukemia (PML) because PML-RAR-{alpha} contributes to leukemogenesis (13) . The expression of tumor suppressor RAR-ß is frequently lost in esophageal, lung, and breast cancers (14, 15, 16) . RAR-ß can be induced by retinoids in many cancer cells, including neuroblastomas, and increases in RAR-ß correlate with growth-inhibitory effects of retinoids, suggesting that rescue of RAR-ß contributes to suppression of tumor growth (17) . Exogenous expression of RARs causes increased sensitivity in teratocarcinoma, lung, and breast cancer cells (18, 19, 20) . Overexpression of RAR-{alpha} and RAR-{gamma} in human keratinocyte tumor cells leads to growth inhibition and accumulation of cells in G1 phase of the cell cycle (21) .

Despite well-documented effects of retinoids as differentiation-inducing agents in many cancer cells, including neuroblastomas, there are not many studies demonstrating the apoptotic effects of retinoids in target cells. Recent studies demonstrate the activated caspase-3, caspase-7, and PARP-1 cleavage in MB (22) , suggesting that apoptotic cell death could play an important role in these tumors. In earlier studies, high concentrations (10 µM) of ATRA were necessary to obtain significant biological effects, and the Fas ligand/Fas system appears to participate in ATRA-induced chemosensitivity of MB cells (23 , 24) . In view of these observations, we investigated whether retinoids and retinoid receptors play a role in MB. To understand the therapeutic potential, ATRA, a natural retinoid, was selected for these studies. In this report, we present evidence for the first time that low concentrations of ATRA are a potent inducer of apoptosis in selected MB cells. Furthermore, we evaluated the mode of cell death and observed that caspase-3 is an important executioner of apoptosis in MB.

Materials and Methods

Cell Culture and Western Blot Analysis.
Human MB cell lines (DAOY, D283, D425, and D458) were cultured in Zinc-Option medium containing 5% fetal bovine serum, 100 units/ml penicillin and 100 µg/ml streptomycin. ATRA was purchased from Sigma, dissolved in ethanol, and kept in the dark at -20°C. MB cell lines growing in mid-log phase were treated with the indicated concentrations of ATRA for different time periods, and the cell lysates were prepared in the buffer as described previously (25) . After the protein concentrations were determined by BCA method (Pierce), 100 µg of protein were subjected to SDS-PAGE and transferred to nitrocellulose membrane. After blocking in 5% nonfat dry milk in Tris buffered saline-triton x100 (TBST), the blots were incubated with primary and secondary antibodies. The protein bands were visualized with enhanced chemiluminescence reagent. RAR and RXR antibodies were purchased from Santa Cruz Biotechnology. PARP-1 antibodies were from PharMingen.

Cell Viability Analysis.
The effect of ATRA on the proliferation of MB cells was determined by MTT method (26) according to the manufacturer’s instructions (Promega). Briefly, 1 x 103 cells were seeded in 96-well plates, incubated at 37°C for 24 h, and treated with either vehicle (0.1% ethanol) or the indicated concentrations of ATRA for 3 days. MTT reagent (10 µl/well) was added and incubated at 37°C for 4 h, and the absorbance was measured at 490 nm. Each experiment was repeated three times in triplicate samples. Results were expressed as the percentage of viable cells over control. The results presented are the average of two independent experiments.

Cell Proliferation Assay.
The ability of ATRA to inhibit DNA synthesis was determined by estimating the amount of BrdUrd incorporation into DNA by a colorimetric immunoassay (Roche). Briefly, cells (2 x 103) were cultured in 48-well plates in the presence of different concentrations of ATRA for 3 days. BrdUrd (10 µM, final concentration) was added, and the cells were reincubated for an additional 24 h. After fixing, the cells were incubated with anti-BrdUrd-peroxidase (100 µl/well) for 2 h at room temperature, and the color developed after adding the trimethyl benzidine was measured at 490 nm. The results were expressed as the percentage inhibition of BrdUrd incorporation by ATRA compared with control.

Anchorage-independent Growth in Soft Agar.
To determine the effect of ATRA on clonal proliferation, soft agar clonogenic assays were performed. After assessing viability, 1 x 105 cells were seeded in the presence of the indicated concentrations of ATRA in 35-mm2 plates in 0.7% agar. After 2 weeks, the plates were stained with 50 µg/ml MTT, and the colonies were scored. All experiments were performed using triplicates, and each experiment was repeated two times, and the results are the average of two independent experiments.

Cell Death Detection Assay.
The extent of apoptotic cell death of MB cells (2 x 104 cells/well in 48-well plates) exposed to different concentrations (50, 100, 200, and 500 nM) of ATRA was determined by a colorimetric immunoassay using Cell Death Detection ELISAplus method (Roche). This assay is based on the quantitation of histone-associated DNA fragments generated in cells undergoing apoptotic cell death. Each experiment was repeated two times, and the results are the average of two independent experiments. Apoptotic cells were detected with DAPI staining. Briefly, cytospins of ATRA-treated cells (500 nM, 3 days) were fixed in 4% paraformaldehyde for 8 min, washed with PBS three times, stained with DAPI (1 µg/ml) for 5 min, and observed under a fluorescence microscope.

Caspase-3 Assays.
Cells (1 x 106) were exposed to 200 nM ATRA for 3 days, and caspase-3 activity was determined by a colorimetric method using DEVD-pNA as a substrate (Roche). The cells were harvested in lysis buffer, and 100 µg of protein were incubated with 100 µM DEVD-pNA for 2 h at 37°C and quantitated at 405 nm. Caspase-3 activity was expressed as fold activation over control. To determine the effect of DEVD-CHO, a caspase-3 inhibitor, experiments were performed by pretreating the cells with 50 µM DEVD-CHO for 2 h, followed by exposure to 500 nM ATRA for 20 h. Determining the extent of cell death by Cell Death Detection ELISAplus method monitored reversal of caspase-3 function. The results are expressed as enrichment of nucleosomes in the cytoplasm of cells treated with ATRA. The experiment was repeated two times, and the results presented are the average of triplicates from two independent experiments.

Statistical Evaluation.
For all of the experiments, data are expressed as mean ± SE. One-way ANOVA was used to assess statistical significance between means. P < 0.05 was considered to be significant.

Results

Expression of RAR and RXR in MB Cell Lines.
The biological effects of retinoids in target cells are mediated by ligand binding to RARs and RXRs. It is not known whether MBs express retinoid receptors. To examine the expression levels of various isoforms of retinoid receptors in MB cell lines (DAOY, D283, D425, and D458) Western blot analysis was performed. As shown in Fig. 1Citation we observed variations in the levels of retinoid receptors (RAR and RXR) between the four MB cell lines. DAOY cells expressed low levels of RXR-{alpha} and RXR-{gamma}. Among the RAR isoforms, the four MB cell lines express RAR-{alpha}. We could not detect RAR-ß, RAR-{gamma}, and RXR-ß. As observed in many other cancer cell lines and tumors, there appears to be a loss of RAR-ß in MB cell lines also.



View larger version (89K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. Expression of retinoid receptors (RXR and RAR) in human MB cell lines. Whole cell lysates from the four MB cell lines were prepared, and 100 µg of protein were separated in 10% SDS-PAGE. The blot was subjected to Western blot analysis and probed with RAR-{alpha}, RXR-{alpha}, and RXR-{gamma} antibodies.

 
ATRA Inhibits the Proliferation of MB Cells.
To examine the growth-inhibitory effects, the four MB cell lines were exposed to different concentrations of ATRA (0.1, 0.2, and 0.5 µM) for 3 days, and cell viability was determined by MTT assay. Results shown in Fig. 2Citation suggest that all three concentrations of ATRA caused a dose-dependent decrease in cell viability. For example, 200 nM ATRA results in 32%, 57%, 53%, and 60% inhibition of cell proliferation in DAOY, D283, D425, and D458 cells, respectively. These results are in contrast to previous studies using 5–10 µM concentrations of RA in combination with cisplatin to achieve significant cell death in Med-3 cells (23 , 24) .



View larger version (21K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. Effect of ATRA on the proliferation of MB cell lines determined by MTT assay. MB cells (DAOY, 500 cells/well; D283, D425, and D458, 1000 cells/well) were seeded in a 96-well plate. The next day, the cells were treated with 100, 200, and 500 nM ATRA for 3 days, and the number of viable cells was determined by MTT assay. The experiment was repeated three times, and the results presented are from two independent experiments. {square}, DAOY; {diamond}, D283; {circ}, D425; {triangleup}, D458.

 
Effect of ATRA on Anchorage-independent Growth of MB Cells.
To determine the in vitro antineoplastic effect, the ability of ATRA to suppress colony formation in soft agar was examined. Because 200 nM ATRA completely suppressed the formation of colonies in D425 and D458 cells, we performed the experiments using 50 and 100 nM ATRA. The number of colonies in control and various treatment groups was counted and is summarized in Fig. 3Citation . From these results, it is evident that 100 nM ATRA caused approximately 90% inhibition of colony formation in D283, D425, and 458 cell lines, indicating that ATRA is a potent inhibitor of clonal proliferation. However, in DAOY cells, 100 nM ATRA caused about 30% inhibition of clonal proliferation.



View larger version (40K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 3. ATRA suppresses the clonal proliferation of MB cells in soft agar. The ability of ATRA to inhibit colony formation in soft agar was determined by plating 1 x 105 cells in 0.7% agar containing 50 and 100 nM of the drug in 6-well plates. After 2 weeks, the plates were stained with MTT reagent, and the number of colonies was counted. The number of colonies represents the average of two independent experiments. *, P < 0.005; **, P < 0.001. {square}, control; , 50 nM;, 100 nM ATRA.

 
ATRA Inhibits the Proliferation of MB Cell Lines.
To understand whether the decrease in the number of viable cells was due to decreased DNA synthesis leading to decreased cell proliferation, the incorporation of BrdUrd into DNA was determined in the presence of 100, 200, and 500 nM ATRA. As shown in Fig. 4Citation , BrdUrd incorporation results reveal that ATRA treatment resulted in a significant decrease in the incorporation of BrdUrd into DNA. We observed marked differences in the BrdUrd incorporation between DAOY and the other three cell lines. For example, 200 nM ATRA caused about 10% inhibition of BrdUrd incorporation into DNA in DAOY cells, whereas the inhibition was about 70% in D283, D425, and D458 cells.



View larger version (41K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 4. ATRA inhibits DNA synthesis as determined by BrdUrd incorporation into DNA. MB cells (2 x 103) were treated with 100, 200, and 500 nM ATRA for 3 days and labeled with BrdUrd (10 µM) for 24 h. Results are expressed as the percentage of inhibition of BrdUrd incorporation relative to ethanol-treated control. Data points are mean of two independent experiments with triplicate determinations. *, P < 0.005; **, P < 0.001. {square}, 100 nM; , 200 nM;, 500 nM ATRA.

 
ATRA Causes a Dose-dependent Increase in Programmed Cell Death in MB Cells.
We consistently observed floating cells (dead cells) in D283, D425, and D458 cells within 24 h after exposure to ATRA. To investigate the mode of cell death, MB cells were treated with 50, 100, 200, and 500 nM ATRA for 3 days, and the extent of DNA fragmentation was quantitated by colorimetric immunoassay. From the results presented in Fig. 5Citation , it was evident that 200 nM ATRA caused 20% cell death in DAOY, whereas in D283, D425, and D458, it caused 49%, 52%, and 81% cell death, respectively. These results suggest that, as observed in MTT and BrdUrd incorporation assays, DAOY cells are relatively resistant, whereas D458 cells were highly sensitive to ATRA. These results indicate that the decrease in the number of viable cells (Fig. 2)Citation could be primarily due to increased apoptosis induced by ATRA. To directly demonstrate apoptosis, MB cells were treated with 500 nM ATRA for 3 days, and the apoptotic nuclei were stained with DAPI. Results shown in Fig. 5CCitation demonstrate apoptosis in D425 and D458 cells. However, under identical conditions, we observed few apoptotic cells in D283 and DAOY cells (data not shown).



View larger version (70K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 5. Quantitation of ATRA-induced cell death in human MB cells. Apoptotic cell death was determined by treating cells (2 x 104 cells/well) with 50, 100, 200, and 500 nM ATRA for 3 days, and the histone-associated DNA fragments were quantitated by cell death assay kit according to the manufacturer’s protocol (Roche). A, data are represented as the difference in absorbance compared with a reference. {diamond}, DAOY; {square}, D283; {triangleup}, D425; {circ}, D458. B, cell death enrichment factor (enhancement of nucleosomes) was calculated by dividing the absorbance of the treated cells by the absorbance of control. The results represent the average of two independent experiments. {square}, DAOY; , D283;, D425;, D458. *, P < 0.005; **, P < 0.001]. C, detection of apoptotic cells with DAPI staining. Morphological appearance of MB cells with and without treatment with ATRA. D425 and D458 cells were treated for 3 days with ATRA (500 nM) and cytospun onto slides. Apoptotic cells were stained with DAPI, and their morphology was visualized by fluorescence microscopy.

 
ATRA Induces the Activation of Caspase-3 in MB Cell Lines.
Results of cell death assay lead us to hypothesize that ATRA might activate caspase-dependent cell death pathways. In addition, a recent immunohistochemical analysis revealed that the two executioners of apoptosis, caspase-3 and -7, are activated in MB primary tumor tissue (22) . These results prompted us to examine whether ATRA-induced cell death was mediated by caspase-3. We treated MB cell lines with 200 nM ATRA for 3 days and determined the caspase-3 activity. Results shown in Fig. 6ACitation demonstrate that ATRA induced caspase-3 activity in all of the four MB cell lines examined. As expected, DAOY cells were relatively resistant (2-fold activation) to ATRA, whereas D458 cells were the most sensitive (20-fold), followed by D425 and D283. To further confirm the contribution of caspase-3 in mediating cell death, we pretreated the MB cell lines with 50 µM caspase-3 inhibitor (DEVD-CHO) for 2 h, followed by exposure to 500 nM ATRA for 20 h. The extent of cell death was determined by cell death immunoassay. We did not perform caspase-3 inhibition studies with DAOY cells because ATRA caused low activation of caspase-3. At the concentrations used in the study, DEVD-CHO did not have any adverse effect in MB cells. Results shown in Fig. 6BCitation indicate that DEVD-CHO partially blocked the cell death observed in presence of ATRA in D283, D425, and D458, supporting the crucial role of caspase-3 in mediating ATRA-induced cell death programs.



View larger version (28K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 6. ATRA induces caspase-3 activity and PARP-1 cleavage in human MB cells. Cells were treated with 200 nM ATRA for 3 days, and caspase-3 activity was determined by colorimetric method according to the manufacturer’s instructions (Biosource International, Inc.). A, caspase-3 activity measured at 405 nm is expressed as fold activation over control. The data presented represent the average of two independent experiments. *, P < 0.005; **, P < 0.001. B, specific caspase-3 inhibitor DEVD-CHO partially blocks ATRA-induced cell death. To further assess the role of caspase-3, we pretreated MB cells with 50 µM DEVD-CHO for 2 h, followed by exposure to 500 nM ATRA for 20 h. Apoptosis/DNA fragmentation was quantitated by cell death ELISA assay (Roche)., DEVD-CHO; , ATRA (500 nM);, ATRA + DEVD-CHO. C, ATRA induces the cleavage of PARP in MB cells. The effect of ATRA on the levels of PARP was determined by Western blot analysis. Cells were exposed to 500 nM ATRA for 3 days, and 100 µg of protein were subjected to Western blot analysis and developed with mouse monoclonal antibodies to PARP-1.

 
Cleavage of PARP-1 in MB Cell Lines Exposed to ATRA.
To understand whether caspase-dependent apoptosis affects downstream substrates of caspase-3, we investigated the proteolytic cleavage of PARP-1 in ATRA-treated cells (27) . PARP-1 plays an important role in DNA bp excision repair, DNA replication, and transcription (28) . Two principal execution caspases, caspase-3 and -7, are responsible for the processing of PARP-1 to 29- and 85-kDa fragments (29) . A recent study identified that caspse-3 and cleaved PARP-1 colocalized in a majority of MB tumors, indicating that caspase-3 may be a major effector caspase leading to cell death in these tumors (22) . In view of these observations, we examined whether caspase-3 activated in ATRA-treated cells leads to alteration in the expression/cleavage of PARP-1. The four MB cell lines were treated with 200 nM ATRA for 3 days, and the cleavage of PARP-1 was determined by Western blot analysis. As shown in Fig. 6CCitation , we observed a decrease in the 116-kDa PARP-1 in all of the cell lines. In the most sensitive cell lines, D425 and D458, we observed the generation of PARP-1 cleavage products (85 kDa). In DAOY and D283 cells, we could not detect the 85-kDa fragment due to detection limits in the Western blots. However, we observed a marked decrease in the 116-kDa fragment compared with control cells, indicating that PARP-1 cleavage occurs in ATRA-treated DAOY and D283 cells. Alternatively, it is possible that the decrease in the 116-kDa fragment could be due to a decline in PARP-1 expression in ATRA-treated DAOY and D283 cells. These results suggest that ATRA induced the activation of caspase-3, which in turn cleaves the substrate PARP-1 in D425 and D458 cells. In contrast, 500 nM ATRA had no effect on the cleavage of PARP-1 in selected lung, colon, prostate, and breast cancer; uterine sarcoma; and neuroblastoma cells (data not shown).

Effect of ATRA on the Expression of Neurofilament-L.
To test whether ATRA initiates the synthesis of neuronal markers, the expression of neurofilament-L, a neuron-specific marker, was analyzed by Western blot analysis. It is known that RA-induced morphological differentiation of neuronal cells is accompanied by induction of specific neuronal markers such as MAP2, GAP43, and neurofilaments. Morphological changes and cytoskeletal protein expression are typical hallmarks of neuronal maturation (30) . Three of the cell lines (D283, D425, and D458) used in the current study were neuronal in origin. When exposed to low concentrations (10–25 nM) of ATRA for prolonged periods of time (2 weeks), there was no evidence of morphological differentiation. As shown in Fig. 7Citation , when exposed to 200 nM ATRA for 3 days, we observed increased expression of neurofilament-L (68 kDa) in D283, D425, and D458 cell lines, suggesting that ATRA initiates the synthesis of differentiation markers in MB cells, which are neuronal in origin. We did not observe similar induction of neurofilaments in DAOY cells, possibly due to glial nature of these cells. These results suggest that ATRA might be activating the neuronal markers in the initial stages of drug exposure and that robust activation of apoptotic programs might dominate in D283, D425, and D458 cells that exhibit neuronal phenotype.



View larger version (17K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 7. Effect of ATRA on neurofilament-L in MB cells. The expression of neurofilament-L was determined by Western blot analysis. MB cells were exposed to 200 nM ATRA for 3 days, and 100 µg of protein were subjected to SDS-PAGE, and the blot was probed with neurofilament-L antibodies.

 
Discussion

The present study demonstrates for the first time that caspases mediate, in part, the apoptotic effects of ATRA in MB cells. The cell viability, BrdUrd incorporation, clonogenic proliferation, and caspase-3 activation data presented in this report strongly suggest that ATRA can be further evaluated as an anticancer agent in MB. Expression of retinoid receptors (RAR and RXR) is critical in mediating the effects of retinoids in target cells. We demonstrate for the first time that the four cell lines selected for this study expressed appreciable levels of RXR-{alpha}, RXR-{gamma}, and RAR-{alpha}. The observed biological effects of ATRA are attributable to its binding to RAR-{alpha} because these cells do not express RAR-ß and RAR-{gamma}, and ATRA does not bind to RXRs. It is possible that these effects are mediated in part by RAR-{alpha} because under the concentrations used in this study, ATRA may not be converted to 9-cis-RA, which might activate RXRs. The results of cell death (Fig. 5)Citation and caspase-3 studies (Fig. 6)Citation suggest that differences in the susceptibility of D283, D425, and D458 cell lines to ATRA may be related to differential expression of RAR-{alpha}, RXR-{alpha}, and RXR-{gamma} or due to activation of receptor-independent mechanisms involving alterations in mitochondrial permeability. DAOY cells, which express low RXR-{alpha} and RXR-{gamma}, are relatively less sensitive to ATRA compared with D283, D425, and D458 cells, which express higher levels of these two receptors and are more sensitive. This is also consistent with low activation of caspase-3 in DAOY cells compared with D458 cells, in which we observed robust caspase-3 activity. In this context, it is important to note that ovarian carcinoma cells that express reduced levels of RAR-{alpha} and RXR-{alpha} are relatively resistant to the effects of ATRA (31) .

Cell type-specific factors associated with RAR-{alpha}/RXR might be different in DAOY cells and contribute to insensitivity. Our results indicate that DAOY cells do not respond like other MB cell lines when treated with ATRA, probably due to glial nature of this cell line. Because many MB-derived cell lines exhibit neuronal and glial characteristics, it is possible that MB cells that are neuronal in phenotype are more sensitive, whereas cells that are glial in phenotype might be relatively resistant to retinoids. In this context, it is important to note that DAOY cells express appreciable levels of glial fibrillary acidic protein and neurofilaments are not induced in this cell line when exposed to differentiation-inducing agents. In contrast D283, D425, and D458 cells do not express glial fibrillary acidic protein but express many markers characteristic of neuronal differentiation including neurofilaments and synaptophysins (32) . Additional studies are necessary to understand the mechanisms involved in the relative insensitivity of DAOY cells to ATRA. To achieve appreciable biological effects, 1–10 µM concentrations of retinoids are essential in many cancer cells (23 , 33 , 34) . There are few reports demonstrating the antiproliferative effects of retinoids in MB cell lines using high concentrations (10 µM) of retinoids (23, 24) . In contrast, our studies for the first time demonstrate that 200–500 nM ATRA induces significant apoptosis in D283, D425, and D458 cells. Our results also indicate that cell lines that are neuronal in origin (D283, D425, and D458) might be more sensitive compared with DAOY cells, which express markers of glial lineage also.

We have provided several lines of evidence indicating that ATRA induces robust apoptosis in part by activating caspase-3, a key executioner of apoptosis. First, we demonstrated a significant dose-dependent increase (Fig. 5)Citation in histone-associated DNA fragmentation (apoptosis) in D283, D425, and D458 cells. The increased cell death corresponded to an increase in the activity of caspase-3, an important mediator of apoptotic cell death (Fig. 6)Citation . Our results indicate that cell-permeable caspase-3 inhibitor DEVD-CHO significantly blocked ATRA-induced apoptosis. This is consistent with the cleavage of PARP-1, a downstream substrate for activated caspase-3. Thus, in D458 cells, which are highly sensitive in all of the in vitro biological assays, we observed high caspase-3 activity and, consequently, increased cleavage of PARP-1. Interestingly, these cells also express the highest levels of RAR-{alpha}, suggesting that this receptor might be important in mediating the actions of ATRA. Additional studies are needed to delineate the role of retinoid receptors in MB. In addition, it is possible that receptor-independent mechanisms might participate in robust apoptosis induced by low doses of ATRA that may be unique to MB cells of neuronal origin. The cell pathways mediating the effects of ATRA appear to be dependent on the cell line under investigation. For example, a novel retinoid, CD347, activates caspase-3 in leukemic cells, but ATRA failed to exert any effect on caspase-3 (35) . In the current study, we provide evidence indicating that ATRA-induced apoptosis in human MB cell lines is mediated in part by caspase pathways. Our observations in the cell culture model system are in agreement with similar colocalization studies of activated caspase-3, caspase-7, and cleavage of PARP-1 in primary tumor tissue (22) . Taken together, results presented in this report indicate that ATRA-induced activation of caspase-3/PARP-1 network contributes significantly in activating apoptotic programs.

In a clinical setting, the toxic side effects of retinoids can be avoided when target cells are highly responsive to low concentrations of retinoids. In many cell culture studies, ATRA, 9-cis-RA, and N-(4-hydroxyphenyl) retinamide (4HPR) inhibit cell proliferation at 1–10 µM concentrations, depending on the cell line and culture conditions (6 , 33 , 34) . In patients who received 300–400 mg/day ATRA, the plasma concentration was about 0.15 µM (36) . Results presented in this study indicate that selected MB cells are sensitive to 0.2 µM ATRA. Therefore, we propose that ATRA or other retinoids might be effective in suppressing MB tumor growth in vivo by caspase-mediated apoptosis. We anticipate that future investigations evaluating the antitumor potential of ATRA or novel retinoids will be necessary in determining their clinical use for MB.

ACKNOWLEDGMENTS

We are grateful to Dr. Friedman and Dr. Darell Bigner for the MB cell lines and Dr. Cosenza for other cancer cell lines. We thank Asha Guttapalli for preparing the manuscript.

FOOTNOTES

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Supported by grants from Joseph Stokes Research Institute and Children’s Brain Tumor Foundation (to C. D. R.) and by Louis Vastardis Neurosurgical Research Fund (to L. N. S.) and Jeffrey Miller Neuro-Oncology Research Fund (to P. C. P.). Back

2 To whom requests for reprints should be addressed, at Joseph Stokes Research Institute #515G, 3615 Civic Center Boulevard, The Children’s Hospital of Philadelphia, Philadelphia, PA 19104. Phone: (215) 590-5718; Fax: (215) 590-9956; E-mail: reddyd{at}email.chop.edu Back

3 The abbreviations used are: MB, medulloblastoma; ATRA, all-trans-retinoic acid; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; BrdUrd, bromodeoxyuridine; PARP, poly(ADP-ribose) polymerase; RAR, retinoic acid receptor; RXR, retinoid X receptor; RA, retinoic acid; DAPI, 4',6-diamidino-2-phenylindole; DEVD-CHO, asp-glu-val-asp-CHO; DEVD-PNA, asp-glu-val-asp-P-nitroanilide. Back

Received 2/ 3/03; revised 5/16/03; accepted 5/17/03.

REFERENCES

  1. Evans A. E., Jenkin R. D., Sposto R., Ortega J. A., Wilson C. B., Wara W., Ertel I. J., Kramer S., Chang C. H., Leikin S. L., Hammond D. The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. J. Neurosug., 72: 572-582, 1990.[Medline]
  2. Yachnis A. T., Rorke L. B., Trojanowski J. Q. Cerebellar dysplasias in humans: development and possible relationship to glial and primitive neuroectodermal tumors of the cerebellar vermis. J. Neuropathol. Exp. Neurol., 53: 61-71, 1994.[Medline]
  3. Tsokos M., Scarpa S., Ross R., Triche T. J. Differentiation of human neuroblastoma recapitulates neural crest development. Study of morphology, neurotransmitter enzymes, and extracellular matrix proteins. Am. J. Pathol., 128: 484-496, 1987.[Abstract]
  4. Sidell N. Retinoic acid-induced growth inhibition and morphologic differentiation of human neuroblastoma cells in vitro. J. Natl. Cancer Inst. (Bethesda), 68: 589-593, 1982.
  5. Abemayor E., Sidell N. Human neuroblastoma cell lines as models for the in vitro study of neoplastic and neuronal cell differentiation. Environ. Health Perspect., 80: 3-15, 1989.[Medline]
  6. Evans T. R., Kaye S. B. Retinoids: present role and future potential. Br. J. Cancer, 80: 1-8, 1999.[CrossRef][Medline]
  7. Hong W. K., Sporn M. B. Recent advances in chemoprevention of cancer. Science (Wash. DC), 278: 1073-1077, 1997.[Abstract/Free Full Text]
  8. Lotan R. Retinoids in cancer chemoprevention. FASEB J., 10: 1031-1039, 1996.[Abstract]
  9. Chambon P. The retinoid signaling pathway: molecular and genetic analyses. Semin. Cell Biol., 5: 115-215, 1994.[CrossRef][Medline]
  10. Carlberg C., Bendik I., Wyss A., Meier E., Sturzenbecker L. J., Grippo J. F., Hunziker W. Two nuclear signalling pathways for vitamin D. Nature (Lond.), 361: 657-660, 1993.[CrossRef][Medline]
  11. Giguere V. Retinoic acid receptors and cellular retinoid binding proteins: complex interplay in retinoid signaling. Endocr. Rev., 15: 61-79, 1994.[Abstract/Free Full Text]
  12. Gudas L. J., Sporn M. B., Roberts A. B. Cellular biology and biochemistry of the retinoids Sporn M. B. Roberts A. B. Goodman D. S. eds. . The Retinoids: Biology, Chemistry, and Medicine, 448-520, Raven Press New York 1994.
  13. Longo L., Pandolfi P. P., Biondi A., Rambaldi A., Mencarelli A., Lo Coco F., Diverio D., Pegoraro L., Avanzi G., Tabilio A., et al Rearrangements and aberrant expression of the retinoic acid receptor {alpha} gene in acute promyelocytic leukemias. J. Exp. Med., 172: 1571-1575, 1990.[Abstract/Free Full Text]
  14. Qiu H., Zhang W., El-Nagaar A. K., Lippman S. M., Lin P., Lotan R., Xu X. C. Loss of retinoic acid receptor-ß expression is an early event during esophageal carcinogenesis. Am. J. Pathol., 155: 1519-1523, 1999.[Abstract/Free Full Text]
  15. Gebert J. F., Moghal N., Frangioni J. V., Sugarbaker D. J., Neel B. G. High frequency of retinoic acid receptor ß abnormalities in human lung cancer. Oncogene, 6: 1859-1868, 1991.[Medline]
  16. Farias E. F., Arasphian A., Bleiweiss I. J., Waxman S., Zelent A., Mira-Y-Lopez R. Retinoic acid receptor {alpha}2 is a growth suppressor epigenetically silenced in MCF-7 human breast cancer cells. Cell Growth Differ., 13: 335-341, 2002.[Abstract/Free Full Text]
  17. Cheung B., Hocker J. E., Smith S. A., Norris M. D., Haber M., Marshall G. M. Favorable prognostic significance of high-level retinoic acid receptor ß expression in neuroblastoma mediated by effects on cell cycle regulation. Oncogene, 17: 751-759, 1998.[CrossRef][Medline]
  18. Moasser M. M., Reuter V. E., Dmitrovsky E. Overexpression of the retinoic acid receptor {gamma} directly induces terminal differentiation of human embryonal carcinoma cells. Oncogene, 10: 1537-1543, 1995.[Medline]
  19. Sheikh M. S., Shao Z. M., Li X. S., Dawson M., Jetten A. M., Wu S., Conley B. A., Garcia M., Rochefort H., Fontana J. A. Retinoid-resistant estrogen receptor-negative human breast carcinoma cells transfected with retinoic acid receptor-{alpha} acquire sensitivity to growth inhibition by retinoids. J. Biol. Chem., 269: 21440-21447, 1994.[Abstract/Free Full Text]
  20. Toma S., Raffo P., Isnardi L., Palumbo R. Retinoids in lung cancer chemoprevention and treatment. Ann. Oncol., 5: 95-102, 1999.
  21. Hatoum A., El-Sabban M. E., Khoury J., Yuspa S. H., Darwiche N. Overexpression of retinoic acid receptors {alpha} and {gamma} into neoplastic epidermal cells causes retinoic acid-induced growth arrest and apoptosis. Carcinogenesis (Lond.), 22: 1955-1963, 2001.[Abstract/Free Full Text]
  22. Puig B., Tortosa A., Ferrer I. Cleaved caspase-3, caspase-7 and poly (ADP-ribose) polymerase are complementarily but differentially expressed in human medulloblastomas. Neurosci. Lett., 306: 85-88, 2001.[CrossRef][Medline]
  23. Liu J., Guo L., Jun-Wei L., Liu N., Li H. All-trans retinoic acid modulates fas expression and enhances chemosensitivity of human medulloblastoma cells. Int. J. Mol. Med., 5: 145-149, 2000.[Medline]
  24. Liu J., Guo L., Luo Y., Li J. W., Li H. All-trans-retinoic acid suppresses in vitro growth and down-regulates LIF gene expression as well as telomerase activity of human medulloblastoma cells. Anticancer Res., 20: 2659-2664, 2000.[Medline]
  25. Gumireddy K., Reddy G. S., Ikegaki N., Binderup L., Sutton N. L., Phillips P. C., Reddy C. D. Anti-proliferative effects of 20-epi-vitamin-D3 analogue, KH1060 in human neuroblastoma: induction of RAR-ß and p21Cip1. Cancer Lett., 190: 51-60, 2003.[CrossRef][Medline]
  26. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods, 65: 55-63, 1983.[CrossRef][Medline]
  27. Widmann C., Gibson S., Johnson G. L. Caspase-dependent cleavage of signaling proteins during apoptosis. a turn-off mechanism for anti-apoptotic signals. J. Biol. Chem., 273: 7141-7147, 1998.[Abstract/Free Full Text]
  28. Lautier D., Lagueux J., Thibodeau J., Menard L., Poirier G. G. Molecular and biochemical features of poly(ADP-ribose) metabolism. Mol. Cell. Biochem., 122: 171-193, 1993.[CrossRef][Medline]
  29. Kaufmann S. H., Desnoyers S., Ottaviano Y., Davidson N. E., Poirier G. G. Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res., 53: 3976-3985, 1993.[Abstract/Free Full Text]
  30. Wang C., Li Y., Wible B., Angelides K. J., Ishii D. N. Effects of insulin and insulin-like growth factors on neurofilament mRNA and tubulin mRNA content in human neuroblastoma SH-SY5Y cells. Brain Res. Mol. Brain Res., 13: 289-300, 1992.[Medline]
  31. Wu S., Zhang Z., Zhang D., Soprano D. R., Soprano K. J. Reduction of both RAR and RXR levels is required to maximally alter sensitivity of CA-OV3 ovarian tumor cells to growth suppression by all-trans retinoic acid. Exp. Cell Res., 237: 118-126, 1997.[CrossRef][Medline]
  32. He X., Carol J., Wikstrand, Friedman H. S., Bigner S. H., Pleasure S., Trojanowski J. Q., Bigner D. D. Differentiation characteristics of newly established medulloblastoma cell lines (D384Med, D425Med, and D458Med) and their transplantable xenografts. Lab. Investig., 64: 833-843, 1991.[Medline]
  33. Suzui M., Masuda M., Lim J. T. E., Albanese C., Pestell R. G., Weinstein I. B. Growth inhibition of human hepatoma cells by acyclic retinoid is associated with induction of p21CIP1 and inhibition of expression of cyclin D1. Cancer Res., 62: 3997-4006, 2002.[Abstract/Free Full Text]
  34. Reynolds C. P., Lemons R. S. Retinoid therapy of childhood cancer. Pediatr. Oncol., 15: 867-910, 2001.
  35. Mologni L., Ponsanelli I., Bresciani F., Sardiello G., Bergamaschi D., Gianni M., Reichert U., Rambaldi A., Terao M., Garattini E. The novel synthetic retinoid 6-[3-adamantyl-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) causes apoptosis in acute promyelocytic leukemia cells through rapid activation of caspases. Blood, 3: 1045-1061, 1999.
  36. Boik J. Lipid-soluble vitamins Farnell S. eds. . Natural Compounds in Cancer Therapy, 470-482, Oregon Medical Press Princeton, MN 2001.



This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
E. I. Fomchenko and E. C. Holland
Mouse models of brain tumors and their applications in preclinical trials.
Clin. Cancer Res., September 15, 2006; 12(18): 5288 - 5297.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. Elisei, A. Vivaldi, L. Agate, R. Ciampi, E. Molinaro, P. Piampiani, C. Romei, P. Faviana, F. Basolo, P. Miccoli, et al.
All-Trans-Retinoic Acid Treatment Inhibits the Growth of Retinoic Acid Receptor {beta} Messenger Ribonucleic Acid Expressing Thyroid Cancer Cell Lines but Does Not Reinduce the Expression of Thyroid-Specific Genes
J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2403 - 2411.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Di, S. Liao, D. C. Adamson, T. J. Parrett, D. K. Broderick, Q. Shi, C. Lengauer, J. M. Cummins, V. E. Velculescu, D. W. Fults, et al.
Identification of OTX2 as a Medulloblastoma Oncogene Whose Product can be Targeted by All-Trans Retinoic Acid
Cancer Res., February 1, 2005; 65(3): 919 - 924.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gumireddy, K.
Right arrow Articles by Reddy, C. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gumireddy, K.
Right arrow Articles by Reddy, C. D.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online